Abstract Details

Title Subjects with Episodic Migraine Treated with DFN-02 (Sumatriptan 10 mg + the permeation enhancer DDM) Report Higher Treatment Satisfaction and Reduced Functional Disability Compared with Placebo

Topic Headache

Presentation(s) P4 - (-)

Poster/Presentation
Number 124

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Elimor Brand-Schieber, PhD (Axovant Gene Therapy) PRESENTER	Dr. Brand-Schieber has received personal compensation for serving as an employee of AbbVie. Dr. Brand-Schieber has stock in AbbVie.
Sagar Munjal, MD (Dr. Reddys)	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��